ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

458
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
bearishWuxi Biologics
05 Jan 2025 09:32

China Healthcare Weekly (Jan.5)-TCM VBP Update, Medical Device VBP Result Is Out, WuXi Bio's Outlook

VBP result of TCM Patent Medicine is released. VBP of cochlear implant/peripheral vascular stent is good for companies. Only when Li Ge buys big...

Logo
471 Views
Share
bearishWuxi Biologics
27 Aug 2024 08:55

Wuxi Biologics (2269.HK) 24H1 - The Best Semi-Annual Report for the Next Three Years?

XDC is the only growth momentum for WuXi Bio. Aggressive expansion/high cost raise concerns about profitability.Facing Japanese/Korean CXO, WuXi...

Logo
305 Views
Share
bearishWuxi Biologics
08 Jun 2023 08:55

Wuxi Biologics (2269.HK) - Some New Business Updates and the Outlook

We analyzed our views based on some new business updates from WuXi Bio’s management. 23H1 seems to be challenging, but whether WuXi Bio can get...

Logo
370 Views
Share
04 Feb 2025 15:19

Hong Kong Connect Flows (January): $18.1bn Inflows

We analyzed the Hong Kong Connect Scheme for January and highlighted flows for Tencent, SMIC, ICBC, China Mobile, Xiaomi and Meituan.

Logo
183 Views
Share
x